Enantioselective Aminohydroxylation of Styrenyl Olefins Catalyzed by an Engineered Hemoprotein by Cho, Inha et al.
Angewandte
International Edition
A Journal of the Gesellschaft Deutscher Chemiker
www.angewandte.org
Chemie
Accepted Article
Title: Enantioselective Aminohydroxylation of Styrenyl Olefins
Catalyzed by an Engineered Hemoprotein
Authors: Inha Cho, Christopher K. Prier, Zhi-Jun Jia, Ruijie K. Zhang,
Tamás Görbe, and Frances H. Arnold
This manuscript has been accepted after peer review and appears as an
Accepted Article online prior to editing, proofing, and formal publication
of the final Version of Record (VoR). This work is currently citable by
using the Digital Object Identifier (DOI) given below. The VoR will be
published online in Early View as soon as possible and may be different
to this Accepted Article as a result of editing. Readers should obtain
the VoR from the journal website shown below when it is published
to ensure accuracy of information. The authors are responsible for the
content of this Accepted Article.
To be cited as: Angew. Chem. Int. Ed. 10.1002/anie.201812968
Angew. Chem. 10.1002/ange.201812968
Link to VoR: http://dx.doi.org/10.1002/anie.201812968
http://dx.doi.org/10.1002/ange.201812968
COMMUNICATION          
 
 
 
 
Enantioselective Aminohydroxylation of Styrenyl Olefins 
Catalyzed by an Engineered Hemoprotein 
Inha Cho[a], Christopher K. Prier[b], Zhi-Jun Jia[a], Ruijie K. Zhang[a], Tamás Görbe
 [c], and Frances H. 
Arnold*[a] 
 
Abstract: Chiral 1,2-amino alcohols are widely represented in 
biologically active compounds from neurotransmitters to antivirals. 
While many synthetic methods have been developed for accessing 
amino alcohols, the direct aminohydroxylation of alkenes to 
unprotected, enantioenriched amino alcohols remains a challenge. 
Using directed evolution, we have engineered a hemoprotein 
biocatalyst based on a thermostable cytochrome c that directly 
transforms alkenes to amino alcohols with high enantioselectivity (up 
to 2500 TTN and 90% ee) under anaerobic conditions with O-
pivaloylhydroxylamine as an aminating reagent. The reaction is 
proposed to proceed via a reactive iron-nitrogen species generated 
in the enzyme active site, enabling tuning of the catalyst's activity 
and selectivity by protein engineering.  
The 1,2-amino alcohol motif is a privileged scaffold present 
in numerous bioactive compounds, drugs, and natural products 
such as neurotransmitters, β-blockers, anti-malarial and anti-HIV 
drugs, and antibiotics.[1] Optically active amino alcohols serve 
other important roles as chiral auxiliaries, ligands, bases, and 
catalysts in asymmetric reactions.[2] Multiple enzymatic routes 
have been developed to access chiral amino alcohols from diols, 
ketones, and esters,[3] or through multistep enzyme cascades 
from styrenyl olefins.[4] To enable single-step enantioselective 
synthesis of amino alcohols from olefins,[5]  several methods, 
such as the pioneering Sharpless asymmetric 
aminohydroxylation of alkenes,[6] have been developed. These 
chemical methods unfortunately suffer from various drawbacks 
related to their scope, selectivity, or the use of toxic metals. 
Furthermore, all of these methods install a nitrogen atom 
bearing a protecting group, necessitating further steps to reveal 
the free amine functionality. Aminooxidation can also be 
achieved by the aziridination of alkenes followed by ring opening, 
but the majority of asymmetric aziridination reactions also 
introduce a nitrogen in a protected form.[7]  
Amination methods that directly transfer a simple NH unit to 
olefins have been developed only recently. In 2014, Kürti and 
coworkers developed rhodium-based catalysts and an aryl 
hydroxylamine precursor for the synthesis of NH-aziridines.[8] 
Morandi and coworkers subsequently reported the synthesis of 
2-amino-1-arylethanols from styrenes, using iron phthalocyanine 
(FePc) as the catalyst and O-pivaloylhydroxylamine triflic acid (1) 
as the nitrogen source (Figure 1A).[9] While further work by 
these laboratories and others has introduced other 
hydroxylamine-based reagents for the direct installation of 
unprotected amines,[10] enantioselective versions have not been 
reported. Given the prevalence of the amino alcohol motif in 
medicinal agents, methods that can directly access this 
structural unit in an enantioselective fashion from abundant 
olefins are highly desirable.  
Our group and others have engineered iron hemoproteins to 
perform nitrene transfer reactions using sulfonyl azides as 
nitrene precursors, demonstrating that enzymes have the ability 
to perform and control the selectivity of challenging non-
biological amination processes.[11] Fasan and coworkers also 
reported enzymatic generation of nitrenes from azidoformates,[12] 
and Hartwig and coworkers reported the use of sulfonyl azides 
for nitrene transfer with artificial iridium-containing 
metalloenzymes.[13] In all of these cases, however, nitrene 
transfer with engineered hemoproteins produces protected 
amine products. Furthermore, the use of azide-based reagents 
may pose safety concerns for large-scale synthesis. 
In a remarkable recent report, Tsutsumi and coworkers 
identified a wild-type cytochrome P450 that performs nitrene 
transfer in benzastatin biosynthesis through the cleavage of an 
N-O bond, demonstrating that hydroxylamines can function as 
nitrene precursors in biological systems (Figure 1B).[14] Inspired 
by nature’s chemistry and Morandi’s FePc catalyst system, we 
aimed to develop a hemoprotein catalyst for one-step production 
of chiral unprotected amino alcohols from olefins, a 
transformation not known in biology. We thought to discover 
such a reaction using nitrene source 1 as the precursor to a 
putative unprotected iron-nitrenoid intermediate 2 (Figure 1C). 
We anticipated that intermediate 2 could react with an olefin, 
adding a nitrogen from the reagent and an oxygen from water to 
form a 1,2-amino alcohol product. In this work, we present the 
directed evolution of an enzyme based on the highly 
thermostable Rhodothermus marinus (Rma) cytochrome c that 
generates and transfers the unprotected iron-nitrenoid for the 
efficient synthesis of chiral amino alcohols from olefins. 
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Figure 1. (A) FePc-catalyzed aminohydroxylation of olefins delivers racemic 
amino alcohol products.
[9]
 (B) The biosynthesis of benzastatins proceeds via 
BezE-catalyzed nitrene formation from an N-acetoxy species, followed by 
intramolecular aziridination.
[14]
 (C) Proposed enzymatic, enantioselective 
aminohydroxylation of alkenes. 
Various catalysts were evaluated for aminohydroxylation 
activity, including cytochrome P450 monooxygenase from 
Bacillus megaterium (P450BM3), P450BM3 variants having the 
Cys400 axial ligand replaced with Ser (P411‘s), the reduced 
heme cofactor alone, iron phthalocyanine (FePc), protoglobins, 
and cytochrome c variants (Supplementary Tables 1 and 2). 
Whereas FePc catalyzes aminohydroxylation of olefins as 
reported,[7] the reduced heme cofactor as well as most of the 
tested hemoproteins showed no or trace activity. The wild-type 
Rhodothermus marinus (Rma) cytochrome c, an extremely 
thermostable (Tm = 106 °C) and small (124 aa) protein which 
coordinates heme using distal methionine and proximal histidine 
ligands in a small solvent-accessible pocket,[15] converted 4-
vinylanisole (3) to aminoalcohol 4 with 4% yield under anaerobic 
conditions and remarkably provided 4 with 32% ee. This result 
indicated that the configuration at the newly formed stereocenter 
is controlled by the protein, suggesting that highly 
enantioselective synthesis of amino alcohols could be achieved 
through protein engineering. 
Rma cytochrome c was used as the template for directed 
evolution to improve activity and enantioselectivity. Starting from 
the distal ligand M100, the closest residues facing the iron of the 
heme cofactor were targeted for sequential site-saturation 
mutagenesis in order to create an active site tailored for the 
putative iron-nitrenoid intermediate and the olefin substrates. 
Nearby residues that do not directly face the heme cofactor were 
also subjected to site-saturation mutagenesis with the 
hypothesis that these residues could impact substrate binding. 
For each round of mutagenesis, beneficial mutations were 
identified by screening for increased product yield and 
enantioselectivity using reverse phase LC-MS and normal phase 
HPLC, respectively. Focusing initially on improving product 
formation, four consecutive rounds of site-saturation 
mutagenesis at residues closest to the heme yielded Rma 
cytochrome c M99V M100S T101P M103G, which produces 
amino alcohol 4 with 360 TTN, a nine-fold improvement over the 
wild-type Rma cytochrome c, and 70% ee (Figure 2A). We then 
selected mutations that provided the greatest improvements in 
enantioselectivity in subsequent rounds. Two additional site 
saturation libraries targeting residues T98 and M76 yielded a 
further 5-fold increase in turnovers (1,800 TTN) and an increase 
in ee to 85%. The final round of site-saturation mutagenesis and 
screening introduced the Y44T mutation. This final variant, Rma 
cytochrome c TQL, provided the product with 2,500 turnovers 
and 90% ee under optimal conditions. 
The crystal structure of Rma wild-type cytochrome c (Figure 
2B) shows the heme iron is coordinated by the distal ligand 
M100, the heme cofactor, and the axial ligand H49, leaving 
neither a free coordination site nor space for substrate binding, 
at least according to the static structure. Nonetheless, the wild 
type protein catalyzes the reaction with 40 TTN. Mutation of 
M100 to serine presumably weakens coordination to iron and 
promotes nitrenoid formation. Residues M99 and M103 in the 
same loop as M100 were also mutated to smaller residues (99V 
and 103G), which may increase the flexibility of the distal loop. 
This may promote alternative conformations of the distal loop, 
potentially allowing new binding poses for the substrates, as 
observed previously in computational studies on a Rma 
cytochrome c catalyst evolved for carbene Si-H insertion.[16] 
Residue Y44 is farther from the heme center but is among the 
residues that surround the active site opening to the aqueous 
environment. Mutation to threonine at this position may improve 
substrate access to the active site. 
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Figure 2. (A) Directed evolution of Rma cytochrome c from wild type to the 
TQL variant. (B) Crystal structure of wild-type Rma cytochrome c (PDB ID: 
3CP5),
[17]
 with mutated residues marked. 
Testing a variety of styrenyl olefin substrates, we found that 
cytochrome c TQL tolerates a range of substitutions on the 
aromatic ring (Scheme 1). Styrenes bearing electron-donating 
as well as -withdrawing substituents at the para position are 
accepted as substrates, undergoing aminohydroxylation with 
hundreds of turnovers in several examples. Meta- and ortho-
substitutions are also tolerated, although these styrenes are 
converted with reduced turnovers and enantioselectivities. The 
TQL variant was also found to be active on - or -substituted 
styrenes to generate amino alcohols 15 and 16. Interestingly, 
examples of activity on internal olefins are rare in both the FePc-
catalyzed aminohydroxylation[9] and hemoprotein-catalyzed 
aziridination with sulfonyl azides.[11d] Aminohydroxylation of 
trans-anethole yielded amino alcohol 16, an analog of the 
neurotransmitter β-hydroxyamphetamine, with 87:13 dr and 95% 
ee. Less activated olefins are challenging substrates, with 4-
phenyl-1-butene and 1-octene providing only trace amounts of 
aminohydroxylation products. We next investigated whether 
aminohydroxylation using TQL could be achieved on a 
preparative scale. A 2.0-mmol scale aminohydroxylation of olefin 
3 using whole cells in phosphate buffer under anaerobic 
conditions furnished product 4 in 61% (204 mg)  isolated yield 
and 85% ee. Aminohydroxylation of trans-anethole was 
performed on 1.0-mmol scale and yielded 95 mg of product 16 
(see Supporting Information for details). The reaction can also 
be performed with purified cytochrome c TQL, proceeding to 
1500 TTN and 85% ee over 24 hours.  
 
Scheme 1. Substrate scope of aminohydroxylation catalyzed by Rma 
cytochrome c TQL variant. Aminoalcohols 4 – 14 are synthesized from 
substituted styrenes, 15 is synthesized from p-isopropenylanisole, and 16 is 
from trans-anethole. Absolute configuration of 4 and 9 is the R-enantiomer, 
and the configuration of other products is assigned by analogy. The major 
diastereomer of product 16 is threo-16 based on NMR. 
Our working mechanistic hypothesis for styrenyl olefin 
aminohydroxylation involves formation of a reactive complex 
between iron and the nitrogen reagent, which may be either the 
nitrene 2 or the corresponding nitrene radical.[18] At this point, 
nitrene transfer to the styrene could proceed to give an aziridine 
intermediate. To test whether this aziridine is a viable reaction 
intermediate, we synthesized racemic 2-phenylaziridine and 
separated the enantiomers via chiral HPLC. Incubating each 
enantiomer in aqueous buffer either with or without the purified 
TQL variant resulted in enantiospecific hydrolysis with inversion 
of configuration at the benzylic center (Scheme 2A). These 
results demonstrate that the aziridine may be a species en route 
to the amino alcohol, with any enantioselectivity conferred by the 
enzyme in the aziridination step persisting in the product. 
Alternatively, the putative nitrene or nitrene radical may engage 
the styrene to produce an iron-bound carbocation intermediate, 
which could be intercepted by water to provide the amino 
alcohol without the intermediacy of an aziridine (Supplementary 
Figure 1).[9] The aminohydroxylation of trans-anethole supports 
such a scenario, as the observed major threo diastereomer is 
inconsistent with a mechanism involving stereospecific 
aziridination and hydrolysis. Further study will be required to 
delineate the exact reaction pathway and characterize the 
reactive iron-nitrogen species.  
We also performed aminohydroxylation of olefin 3 with a 
different nitrene precursor, O-(tert-butoxycarbonyl)-
hydroxylamine (17). When the reaction was performed using 
catalyst-harboring E. coli whole cells, aminohydroxylation of 3 
with reagent 17 yielded amino alcohol 4 with 1,500 TTN with 
93% ee (Scheme 2B). This demonstrates that hemoproteins 
can utilize different reagents to access the putative unprotected 
nitrenoid intermediate. The effect of the nitrene precursor on the 
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reaction may provide an additional handle for reaction 
engineering. 
 
Scheme 2. (A) Enantiospecific hydrolysis of 2-phenylaziridine occurs in both 
the presence and absence of the TQL cytochrome c variant, indicating that the 
aziridine is a viable intermediate en route to enantioenriched products. (B) An 
alternative nitrene source 17 also provides the amino alcohol product 4. 
Wild-type Rma cytochrome c displayed a limited ability to 
catalyze the amination of styrenyl olefins with hydroxylamine 
reagent 1. Directed evolution improved this promiscuous 
function, delivering the cytochrome c TQL variant, an efficient 
catalyst for the synthesis of unprotected amino alcohols directly 
from alkenes. The heme cofactor of TQL is based on the most 
widely available transition metal in the Earth’s crust, iron, and 
the enzyme exhibits levels of activity and selectivity toward 
aminohydroxylation that have been difficult to achieve with 
diverse synthetic methods. As the catalyst is fully genetically 
encoded, it can be tuned by directed evolution and produced 
and used in bacteria. This approach also provides a path to 
taming and utilizing an unusual and synthetically valuable 
unprotected nitrene equivalent, potentially enabling biocatalytic 
solutions to further challenges in direct amination chemistry.  
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